Table 4.
Relationship between immunochemical features and tumor stage
| Target expression | Ta | Tis (CIS) | T1 | T2 | >T3, N+ or M+ | p -value | Target expression | Ta | Tis (CIS) | T1 | T2 | >T3, N+ or M+ | p -value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VEGFA | APOE | ||||||||||||
| 1 | 10 (25.0%) | 5 (29.4%) | 18 (33.3%) | 6 (25.0%) | 8 (28.6%) | 0.670 | 1 | 13 (27.7%) | 1 (6.3%) | 9 (15.3%) | 7 (24.1%) | 0 (0%) | 0.009 |
| 2 | 6 (15.0%) | 5 (29.4%) | 17 (31.5%) | 6 (25.0%) | 9 (32.1%) | 2 | 14 (29.8%) | 6 (37.5%) | 14 (23.7%) | 5 (17.2%) | 5 (13.9%) | ||
| 3 | 10 (25.0%) | 4 (23.5%) | 9 (16.7%) | 7 (29.2%) | 7 (25.0%) | 3 | 10 (21.3%) | 5 (31.3%) | 13 (22.0%) | 6 (20.7%) | 17 (47.2%) | ||
| 4 | 14 (35.0%) | 3 (17.6%) | 10 (18.5%) | 5 (20.8%) | 4 (14.3%) | 4 | 10 (21.3%) | 4 (25.0%) | 23 (39.0%) | 11 (37.9%) | 14 (38.9%) | ||
| MMP9 | SERPINA1 | ||||||||||||
| 1 | 5 (11.6%) | 4 (7.1%) | 4 (13.8%) | 0.036 | 1 | 11 (25.0%) | 2 (13.3%) | 16 (27.6%) | 3 (10.7%) | 2 (5.9%) | 0.036 | ||
| 2 | 15 (34.9%) | 5 (35.7%) | 16 (28.6%) | 4 (13.8%) | 5 (14.3%) | 2 | 10 (22.7%) | 2 (13.3%) | 12 (20.7%) | 9 (32.1%) | 4 (11.8%) | ||
| 3 | 13 (30.2%) | 5 (35.7%) | 22 (39.3%) | 7 (24.1%) | 11 (31.4%) | 3 | 10 (22.7%) | 4 (26.7%) | 19 (32.8%) | 6 (21.4%) | 9 (26.5%) | ||
| 4 | 10 (23.3%) | 4 (28.6%) | 14 (25.0%) | 14 (48.3%) | 19 (54.3%) | 4 | 13 (29.5%) | 7 (46.7%) | 11 (19.0%) | 10 (35.7%) | 19 (55.9%) | ||
| MMP10 | SDC1 | ||||||||||||
| 1 | 11 (25.6%) | 8 (57.1%) | 12 (21.8%) | 2 (6.9%) | 3 (8.3%) | 0.036 | 1 | 6 (14.3%) | 4 (21.1%) | 5 (8.5%) | 5 (17.2%) | 7 (20.0%) | 0.021 |
| 2 | 9 (20.9%) | 2 (14.3%) | 10 (18.2%) | 8 (27.6%) | 6 (16.7%) | 2 | 9 (21.4%) | 6 (31.6%) | 5 (8.5%) | 8 (27.6%) | 6 (17.1%) | ||
| 3 | 10 (23.3%) | 3 (21.4%) | 12 (21.8%) | 9 (31.0%) | 11 (30.6%) | 3 | 13 (31.0%) | 6 (31.6%) | 17 (28.8%) | 8 (27.6%) | 16 (45.7%) | ||
| 4 | 13 (30.2%) | 1 (7.1%) | 21 (38.2%) | 10 (34.5%) | 16 (44.4%) | 4 | 14 (33.3%) | 3 (15.8%) | 32 (54.2%) | 8 (27.6%) | 6 (17.1%) | ||
| SERPINE1 | ANG | ||||||||||||
| 1 | 19 (45.2%) | 8 (53.3%) | 12 (21.4%) | 2 (7.1%) | 3 (8.6%) | 0.0003 | 1 | 0 (0%) | 1 (5.9%) | 0 (0%) | 3 (10.3%) | 0 (0%) | <0.0001 |
| 2 | 7 (16.7%) | 1 (6.7%) | 11 (19.6%) | 4 (14.3%) | 8 (22.9%) | 2 | 23 (50.0%) | 8 (47.1%) | 16 (27.1%) | 6 (20.7%) | 1 (2.8%) | ||
| 3 | 9 (21.4%) | 5 (33.3%) | 15 (26.8%) | 5 (17.9%) | 9 (25.7%) | 3 | 12 (26.1%) | 2 (11.8%) | 24 (40.7%) | 10 (34.5%) | 15 (41.7%) | ||
| 4 | 7 (16.7%) | 1 (6.7%) | 18 (32.1%) | 17 (60.7%) | 15 (42.9%) | 4 | 11 (23.9%) | 6 (35.3%) | 19 (32.2%) | 10 (34.5%) | 20 (55.6%) | ||
| IL8 | |||||||||||||
| 1 | 19 (41.3%) | 7 (43.8%) | 20 (33.3%) | 4 (13.8%) | 2 (5.4%) | 0.001 | |||||||
| 2 | 12 (26.1%) | 3 (18.8%) | 16 (26.7%) | 4 (13.8%) | 6 (16.2%) | ||||||||
| 3 | 6 (13.0%) | 1 (6.3%) | 11 (18.3%) | 10 (34.5%) | 8 (21.6%) | ||||||||
| 4 | 9 (19.6%) | 5 (31.3%) | 13 (21.7%) | 11 (37.9%) | 21 (56.8%) | ||||||||
| CA9 | |||||||||||||
| 1 | 12 (26.7%) | 4 (23.5%) | 10 (16.7%) | 7 (24.1%) | 2 (5.3%) | 0.308 | |||||||
| 2 | 12 (26.7%) | 5 (29.4%) | 9 (15.0%) | 6 (20.7%) | 14 (36.8%) | ||||||||
| 3 | 9 (20.0%) | 3 (17.6%) | 17 (28.3%) | 6 (20.7%) | 10 (26.3%) | ||||||||
| 4 | 12 (26.7%) | 5 (29.4%) | 24 (40.0%) | 10 (34.5%) | 12 (31.6%) |